Ma YS - Search Results

1

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I. Longley BJ, et al. Among authors: ma ys. Nat Genet. 1996 Mar;12(3):312-4. doi: 10.1038/ng0396-312. Nat Genet. 1996. PMID: 8589724

2

Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments.

Longley BJ, Tyrrell L, Lu S, Ma Y, Klump V, Murphy GF. Longley BJ, et al. J Invest Dermatol. 1997 May;108(5):792-6. doi: 10.1111/1523-1747.ep12292240. J Invest Dermatol. 1997. PMID: 9129234 Free article.

3

Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.

Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Ma Y, et al. J Invest Dermatol. 1999 Feb;112(2):165-70. doi: 10.1046/j.1523-1747.1999.00488.x. J Invest Dermatol. 1999. PMID: 9989791 Free article.

4

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y. Longley BJ Jr, et al. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14. doi: 10.1073/pnas.96.4.1609. Proc Natl Acad Sci U S A. 1999. PMID: 9990072 Free PMC article.

5

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. Ma Y, et al. Blood. 2002 Mar 1;99(5):1741-4. doi: 10.1182/blood.v99.5.1741. Blood. 2002. PMID: 11861291 Free article.

6

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.

Ma Y, Carter E, Wang X, Shu C, McMahon G, Longley BJ. Ma Y, et al. J Invest Dermatol. 2000 Feb;114(2):392-4. doi: 10.1046/j.1523-1747.2000.00888.x. J Invest Dermatol. 2000. PMID: 10652004 Free article.

7

New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.

Longley BJ, Ma Y, Carter E, McMahon G. Longley BJ, et al. Hematol Oncol Clin North Am. 2000 Jun;14(3):689-95. doi: 10.1016/s0889-8588(05)70302-6. Hematol Oncol Clin North Am. 2000. PMID: 10909046 Free article. Review.

8

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

Longley BJ, Reguera MJ, Ma Y. Longley BJ, et al. Leuk Res. 2001 Jul;25(7):571-6. doi: 10.1016/s0145-2126(01)00028-5. Leuk Res. 2001. PMID: 11377682 Review.

9

Chymase cleavage of stem cell factor yields a bioactive, soluble product.

Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Langley K, Lu HS, Schechter NM. Longley BJ, et al. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9017-21. doi: 10.1073/pnas.94.17.9017. Proc Natl Acad Sci U S A. 1997. PMID: 9256427 Free PMC article.

10

Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.

Hartmann K, Wardelmann E, Ma Y, Merkelbach-Bruse S, Preussner LM, Woolery C, Baldus SE, Heinicke T, Thiele J, Buettner R, Longley BJ. Hartmann K, et al. Gastroenterology. 2005 Sep;129(3):1042-6. doi: 10.1053/j.gastro.2005.06.060. Gastroenterology. 2005. PMID: 16143141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

296 results

Search Page

Filters